Meredith WadmanNovavax, the small, Maryland-based company that has been struggling for months to bring its promising protein-based COVID-19 vaccine to market, announced a setback yesterday in its quest for an emergency use authorization (EUA) in the United States, sending its share prices tumbling today.
The U.S. government has ordered Novavax to stop making vaccine in the United States and said it will offer the company no more funding until it passes muster with the Food and Drug Administration’s (FDA’s) strict manufacturing requirements, such as ensuring each lot of vaccine has the same potency.“The U.S.
government has recently instructed [us] to prioritize alignment” with FDA’s methods for ensuring consistency in manufacturing, the.